Methicillin-resistant Staphylococcus aureus in Horses and Horse Personnel, 2000–2002 by Weese, J.S. et al.
Methicillin-resistant  Staphylococcus aureus (MRSA)
infection was identified in 2 horses treated at a veterinary
hospital in 2000, prompting a study of colonization rates of
horses and associated persons. Seventy-nine horses and
27 persons colonized or infected with MRSA were identi-
fied from October 2000 to November 2002; most isolations
occurred in a 3-month period in 2002. Twenty-seven (34%)
of the equine isolates were from the veterinary hospital,
while 41 (51%) were from 1 thoroughbred farm in Ontario.
Seventeen (63%) of 27 human isolates were from the vet-
erinary hospital, and 8 (30%) were from the thoroughbred
farm. Thirteen (16%) horses and 1 (4%) person were clin-
ically infected. Ninety-six percent of equine and 93% of
human isolates were subtypes of Canadian epidemic
MRSA-5, spa type 7 and possessed SCCmecIV. All tested
isolates from clinical infections were negative for the
Panton-Valentine leukocidin genes. Equine MRSA infec-
tion may be an important emerging zoonotic and veteri-
nary disease. 
M
ethicillin was first introduced in human medicine in
the 1950s for the treatment of penicillin-resistant
staphylococci, and within a few years, methicillin-resistant
isolates of Staphylococcus aureus (MRSA) were identified
(1). Since then, MRSA has emerged as an important prob-
lem in human medicine internationally, especially in the
hospital setting (2–6). Methicillin resistance is mediated
by production of an altered penicillin-binding protein
(PBP2a), which confers resistance to all β-lactam antimi-
crobial agents. The gene that encodes this altered PBP,
mecA, resides on a large, mobile genetic element called the
staphylococcal chromosomal cassette mec  (SCCmec).
Three types of SCC (types I, II, and III) were originally
described in hospital-acquiredMRSAstrains, most of them
isolated before 1990. A fourth type (type IV) was recently
described, initially in community-acquiredMRSA isolates
(2–4). Although MRSA have been typically hospital
acquired (5,6), reports of community-acquired MRSA in
persons have increased (7–9). In Canada, 6 epidemic
clones, designated CMRSA(Canadian epidemic MRSA) 1
through 6 based on pulsed-field gel electrophoresis
(PFGE), are recognized (10,11). In addition to PFGE,
SCCmec typing and DNA sequencing of the X region of
the protein A gene (spa typing) can be used to further dif-
ferentiate strains for epidemiologic analysis (12).
The role of MRSA in veterinary medicine has not been
well characterized. Isolation of MRSA has been reported
in horses, cattle, and dogs (13–20). In addition, MRSA
infection in 2 horses treated at the Ontario Veterinary
College Veterinary Teaching Hospital (OVC-VTH) was
first documented in 2000. To evaluate the apparent emer-
gence of MRSAinfection and colonization in horses, nasal
swabs from horses and persons at OVC-VTH and a select
group of farms from southern Ontario were cultured. 
Materials and Methods
Veterinary Hospital Facility 
The Large Animal Clinic at OVC-VTH is a tertiary-
care referral center with a caseload of ≈2,000 horses per
year. Hospital personnel that are in contact with horses
include senior clinicians (internists, surgeons, other spe-
cialists), residents, interns, veterinary technicians, agricul-
tural assistants, and veterinary students. 
Sampling Procedures
A limited organized MRSA screening of horses at
OVC-VTH was performed from October 1 to October 5,
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more thorough screening program was performed from
May 17 to November 16, 2002, after further cases were
recognized. With this program, nasal swabs were collected
from all horses at the time of admission, weekly during
hospitalization, and at the time of discharge. Intermittent
screening of horses on 1 Ontario breeding farm (farm A)
was performed from May 11 to September 15, 2002, after
infected horses were identified. Nasal swabs were collect-
ed from horses at 9 other Ontario farms after MRSAinfec-
tion in a resident horse was identified at OVC-VTH. Nasal
swabs were collected from all horses that were present on
these farms on the day of sampling.
Voluntary screening of OVC-VTH Large Animal Clinic
personnel was performed on 2 occasions in 2002 in
response to identification of clusters of nosocomial MRSA
colonization in horses. Periodic nasal cultures of horses
and personnel were initiated at farm A from May 11 to
September 15, 2002. 
For persons, cotton-tipped swabs were used to sample
both anterior nares. For horses, the swab was inserted ≈10
cm into 1 anterior nare and rubbed against the mucosa as
the swab was removed. Swabs were placed in liquid
Stuart’s or Amies medium and stored at 4°C until process-
ing. Colonization or infection identified within 72 h of
admission was classified as community acquired. 
MRSA Identification, Characterization, and Typing
Nasal swab samples were injected onto mannitol-salt
agar with 2 µg/mL oxacillin and incubated aerobically at
35°C for 48 h. Colonies were identified as S. aureus based
on colony morphology, Gram stain appearance, ability to
ferment maltose, and positive tube coagulase test or latex
agglutination test (Pastorex Staph Plus, Bio-Rad
Laboratories Ltd, Mississauga, Canada).
Screening for methicillin resistance in all S. aureus was
by growth on Mueller-Hinton agar with 4% NaCl and 6
µg/mL oxacillin. Confirmation of methicillin resistance
was by detection of PBP 2a by using the MRSA SCREEN
antibody kit (Denka Seiken Co. Ltd, Tokyo, Japan) (21). 
Antimicrobial susceptibility testing was performed by
broth microdilution as per NCCLS guidelines (22).
Detection of inducible erm  gene-mediated clindamycin-
resistance (MLSB phenotype) was performed by using the
double disk diffusion method as described in M100-S14
NCCLS 2004 Informational Supplement (23). 
Isolates were typed by using PFGE after DNA extrac-
tion and SmaI digestion (24). PFGE images were read
manually by 1 investigator (B.W.), and related isolates
were divided into subtypes by using an arbitrary naming
system based on previously described principles (25).
Further typing by DNA sequence analysis of the X region
of the protein A gene (spa typing) and SCCmec typing
were performed, as has been described, on isolates from
those with clinical infections, atypical isolates from colo-
nized horses, and a random sample of isolates from colo-
nized horses (12,26). 
Isolates from those with clinical infection were tested
for the presence of the Panton-Valentine leukocidin (PVL)
genes by polymerase chain reaction (PCR) and by molec-
ular beacon with the lukF component of pvl. Amplification
of the pvl gene was performed by using the following
primers: LukS-PV: GGCCTTTCCAATACAATATTGG;
and LukF-PV: CCCAATCAACTTCATAAATTG.
Thermal cycling consisted of initial heating at 95°C for
5 min followed by 35 cycles of denaturation (1 min at
94°C), annealing (30 s at 57°C), and extension (1 min at
72°C). The beacon experiment was carried out using the
following beacon and primers: lukF beacon: 5′ 6-FAM d
(CGCGAAGAATTTATTGGTGTCCTATCTCGAT-
CGCG) DABCYL 3′, LukF F: 5′-GCCAGTGTTATCCA-
GAGG-3′, LukF R: CTATCCAGTTGAAGTTGATCC-3′.
Quantitative real-time PCR mixture contained 1x I.Q.
supermix (Bio-Rad Laboratories Ltd., Hercules, CA,
USA), 0.1 µmol/L each molecular beacon, 0.5 µmol/L of
each primer, and DNA template.The thermal cycling pro-
gram consisted of 10 min on a spectrofluorometricthermal
cycler at 95°C, followedby 45 cycles of 30 s at 95°C, 30 s
at 50°C,and 30 s at 72°C. 
Statistical Analysis
Duration of carriage by adult horses versus foals was
compared by using the Mann-Whitney test. The incidence
of intermittent MRSA shedding by adult horses and foals
was compared by using Fisher exact test. A p value of
<0.05 was considered significant for all comparisons.
Results
In total, MRSAwas isolated from 79 horses and 27 per-
sons. Two equine isolations occurred in 2000, 5 in 2001,
and 72 in 2002. Of the 79 equine cases, 27 (34%) were in
horses that had been hospitalized at OVC-VTH, 41 (52%)
were from 1 thoroughbred farm (farm A), and 11 (14%)
were from other Ontario farms. Twenty-four of the 79
(30%) horses were adults; the remaining 55 (70%) were <1
year of age.
Clinical infections developed in 13 (16%) horses at 1 or
more body sites. Incision or wound infections (n = 6),
infection from intravenous catheter (n = 2), bacteremia
(n = 2), pneumonia (n = 1), infection from surgical implant
(n = 1), septic arthritis (n = 1), omphalophlebitis (n = 1),
gluteal abscess (n = 1), and osteomyelitis (n = 1) were
identified. In 2 neonatal foals, MRSA was isolated from
the nares, blood, and intravenous (jugular) catheter; septic
arthritis developed in 1 of the foals. The intravenous
catheter was thought to be the original site of infection in
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a history of contact with colonized persons; 2 of these also
had contact with infected or colonized horses. No history
of known contact with colonized humans or horses was
present in 3 (15%) cases. Although many of the clinically
infected horses were seriously ill and required prolonged
hospitalization, MRSAwas implicated directly in the death
of 1 horse as a result of severe osteomyelitis.
The clinical significance of 3 isolates was unclear. One
was from a routine prebreeding uterine swab from a mare
without any apparent clinical abnormalities or history of
reproductive disease. Two were from uterine swabs from
2 mares following abortions. Whether MRSA was the
cause of abortion in either case was unclear. The remain-
ing 63 (80%) horses had subclinical infection and were
nasal carriers. 
Typing was performed on all 27 OVC-VTH isolates, 37
(90%) of 41 farm A isolates, and all 11 isolates from other
Ontario farms. The remaining 4 isolates, all from colo-
nized horses, were lost before being typed. Of the 75 test-
ed isolates, including all 13 isolates from clinical
infections, 72 (96%) were identified as CMRSA 5. This
strain is closely related to an international epidemic strain
designated the “archaic clone” (ATCC BAA-38) (11). Nine
different subtypes of CMRSA-5 were identified from hors-
es. All 12 tested isolates from horses with clinical infec-
tions contained SCCmecIV, were spa type 7, and did not
contain PVL genes. The 2 isolates from postabortion uter-
ine swab specimens also contained SCCmecIV and were
negative for PVLgenes; however, 1 was spa type 7 and the
other spa type 235. Five isolates from colonized horses
were tested, and all also contained SCCmecIV and were
spa type 7. All 3 non-CMRSA-5 isolates were obtained
from farm Aand were similar to, but distinguishable from,
CMRSA-2, spa type 2 and contained SCCmecIV. 
MRSAinfection or colonization was suspected of being
nosocomial in 17 (63%) of 27 OVC-VTH cases and com-
munity-acquired in 3 (11%) cases. Origin of infection was
unclear in the remaining 7 (26%) cases. In these cases, the
nasal swab specimen was not collected on admission;
MRSA was isolated from the first sample collected >72
hours after admission, and horses were admitted from farm
A during a time when numerous colonized horses were on
the farm. 
Sixty-eight of the equine isolates were obtained during
periods of organized screening at OVC-VTH or on horse
farms. The remaining 11 isolates were from clinical speci-
mens submitted directly by primary care veterinarians to a
diagnostic laboratory and are excluded from prevalence
calculations. In 2000, MRSA was isolated from the nasal
passages of 2 (4%) of 57 horses, including the 2 initial
clinical cases. In 2002, MRSA was isolated from 25 (8%)
of 320 horses at OVC-VTH and 41 (13%) of 321 horses on
farm A. Of the 9 other farms evaluated after identification
of an infected or colonized horse at OVC-VTH, MRSA
was only identified on 1 farm, where 3 (5%) of 64 of hors-
es were colonized. MRSA was not isolated from any of
277 horses from 8 other Ontario farms. 
MRSA was isolated from 27 persons; 17 (14%) of 125
of tested OVC-VTH personnel, 8 (12%) of 67 of farm A
personnel, 1 owner of a horse with an MRSAwound infec-
tion and the spouse of a colonized OVC-VTH clinician.
Three human isolates were obtained in 2000, and 24 were
obtained in 2002. Only 1 (4%) was from a source with
clinical infection, an OVC-VTH veterinarian with a tattoo
site infection. That person was infected with CMRSA-5
subtype H12, a strain that contained SCCmecIV, was spa
type 7, and was PVL negative, and that strain was isolated
from 2 horses that had been under that person’s care for a
week before the wound infection developed. All but 1 col-
onized person (96%) had previous contact with 1 or more
MRSA-positive horses; in 24 (89%) of 27 persons, recent
contact with a horse infected with an indistinguishable
subtype was documented. The colonized spouse of the col-
onized OVC-VTH clinician reported no contact with hors-
es; however, isolates from both of these persons were
indistinguishable from an isolate recovered from a horse
under that clinician’s care. CMRSA-5 was isolated from
26 (96%) of 27 persons. One person harbored both
CMRSA-5 and the CMRSA-2–like isolate in his nose at
the same time. This person was a veterinarian from farm A,
which was the origin of the 3 horses colonized with this
strain. Nine different subtypes of CMRSA-5 were identi-
fied among human isolates. 
All but 2 of the human isolates were obtained during
organized screening of personnel from OVC-VTH or
selected Ontario horse farms. In 2000, MRSAwas isolated
from 2 (10%) of 21 humans at the OVC-VTH. In 2002,
MRSA was isolated from 15 (12%) of 127 persons at
OVC-VTH and 8 (12%) of 68 from farm A. 
Antimicrobial susceptibility testing was performed on
67 of the 72 equine and all 26 human CMRSA-5 isolates,
and the 5 CMRSA-2–related strains. Five of the equine
CMRSA-5 isolates were unavailable for testing. All 101
MRSA isolates tested were susceptible to ciprofloxacin,
clindamycin, fusidic acid, linezolid, mupirocin, quin-
upristin-dalfopristin, and vancomycin. The range of
oxacillin MIC was 1–>32 µg/mL, and although 21.8% of
strains had oxacillin MIC of <2 µg/mL at 24 h, all such
strains grew on the NCCLS oxacillin screen agar and pro-
duced the PBP2a protein. Isolates of both CMRSA-5 and
CMRSA-2–related strains that were erythromycin-resist-
ant were found to be inducibly resistant to clindamycin
when challenged by using the double disk approximation
test. The remaining susceptibility test results are presented
in the Table. 
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This study has identified the largest number of reported
cases of clinical MRSA infection in horses and horse per-
sonnel. It also identified extensive nasal colonization in
horses and horse personnel from a veterinary hospital and
horse farm, nosocomial infection in a veterinary hospital
setting with clinical illness in horses, and for the first time,
clinical infection in 1 person working with infected horses.
The subtyping information and timing of isolation provide
solid evidence supporting both human-to-horse and horse-
to-human transmission. 
The prevalence of MRSA colonization in horses at the
OVC-VTH was 4% in 2000 and 8% in 2002; however, care
must be taken when interpreting these data because screen-
ing was performed during 2 periods that followed identifi-
cation of clinical MRSA infection in horses at the facility.
Similar limitations are present with the prevalence data
regarding MRSA colonization on breeding farms, which
ranged from 0% to 13% and were based on screening after
identification of MRSA infection or colonization at OVC-
VTH in horses from these farms. The prevalence of human
colonization at OVC-VTH and 1 Ontario horse farm is of
concern, particularly because of the likelihood of transmis-
sion between horses and humans on these farms. As with
horses, the prevalence data in humans must be interpreted
with care because of the nature of sampling. Further stud-
ies are required to determine the prevalence of MRSA
infection and colonization in horses and humans at veteri-
nary hospitals and equine farms. One well-recognized
human S. aureus strain, CMRSA-5, a relatively uncommon
isolate in Canada (11), has the ability to colonize the nose
of horses and to spread between horses and between horses
and persons on farms and within a veterinary hospital set-
ting. The PFGE pattern of the CMRSA-5 isolates was sim-
ilar to the PFGE patterns published in a previous report of
MRSAinfection in horses (13). This finding, along with the
isolation of CMRSA-5 from horses in Prince Edward
Island, Canada (J.S. Weese et al., unpub. data) and
Colorado, USA (P. Morley, pers. comm.) that did not have
any contact with colonized Ontario horses or horse person-
nel, further suggests that CMRSA-5 may be more dissemi-
nated in the horse population beyond Ontario. 
Why MRSA has emerged in the equine population is
unclear. It may reflect increased exposure of horses to
MRSA-infected persons, a unique ability of CMRSA-5 to
colonize horses, the increasing use of certain antimicrobial
drugs in veterinary medicine, or a combination of these
factors. Several recent investigations in humans suggest
that the fluoroquinolones themselves may actually predis-
pose patients to infection with or carriage of MRSA
(27,28). Two case-control studies examining risk factors
for MRSA found a significant association between fluoro-
quinolone exposure and MRSA isolation or infection
(4,29). 
Whether fluoroquinolone use in horses has facilitated
emergence of MRSA is not known, since no current data
exist on fluoroquinolone use in veterinary medicine.
Enrofloxacin is widely used in some sectors of the Ontario
horse population, particularly racing horses; however, it is
rarely prescribed at OVC-VTH and uncommonly used on
breeding farms (J.S. Weese, unpub. data). 
While MRSAhas been considered primarily a hospital-
associated pathogen in humans (10), the increasing inci-
dence of community-acquired infection is concerning
(8,9,30,31). Similar to the equine and equine-associated
cases reported here, community-acquired infection with
SCCmecIV strains has been reported in humans (32–34).
Most reports of community-acquired-MRSA in humans
involve skin and soft tissue infections, and production of
PVLhas been implicated as the possible virulence factor in
community-associated MRSA infection in humans
(31,35). None of the isolates from clinical equine or
equine-associated infections in this study contained PVL
genes; however, definitive conclusions regarding the role
of PVLin equine-associated infection cannot be made with
the reasonably small number of clinical isolates evaluated
here. Isolates in this study were also multidrug resistant, in
contrast to results of many reports of community-associat-
ed MRSA in humans (36,37). Therefore, determining the
origin of these isolates (community versus hospital) is not
straightforward and requires further study. 
The lack of proven, safe, and acceptable options of
eradication of nasal colonization in horses creates potential
management problems. To date, isolation of infected hors-
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Weese, unpub data). However, such methods may be diffi-
cult on farms, particularly if colonization is prolonged. 
Our study has shown that MRSA infection may be an
emerging disease in horses, which agrees with earlier
reports (13,14). MRSA infection also may become an
important nosocomial problem in the veterinary hospital
setting and become endemic on horse farms, particularly in
foals. Because of the extensive movement of horses, espe-
cially thoroughbreds and standardbreds, between and with-
in Canada and the United States, MRSA colonization and
infection may be more widespread than recognized.
Emergence of MRSAas an equine pathogen is of addition-
al concern because horses may be a community reservoir
of MRSA and source of infection or reinfection for per-
sons. In view of the size of the North American horse pop-
ulation and the frequent close contact between many
persons and horses, this concern must not be dismissed.
Further study is required to clarify the role of this pathogen
in equine disease and transmission between horses and
humans. 
Dr. Weese is an associate professor in the Department of
Clinical Studies, Ontario Veterinary College, University of
Guelph. His current research interests include multidrug-resistant
bacteria (particularly interspecies transmission of such bacteria),
zoonotic diseases, and veterinary infection control.
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